[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vir Biotechnology: Can the Pipeline Actually Replace What the Partnership Revenue Isn't Delivering

Vir Biotechnology (VIR) reports second-quarter 2026 earnings after the close on August 5, 2026, with analysts expecting a dramatic turnaround to profitability. The central question: can the clinical-stage biotech deliver on its $0.83 consensus EPS estimate—a stark reversal from the $0.85 loss posted last quarter—or will execution challenges derail the anticipated inflection point?

Vir Biotechnology is a clinical-stage immunology company focused on developing treatments for infectious diseases and cancer, leveraging antibody platform technologies. The company's pipeline includes programs targeting hepatitis B, influenza, and HIV, with recent attention centered on its collaboration revenues and clinical trial progress.

Fundamentals

See More
  • Market Capitalization, $K 1,546,539
  • Shares Outstanding, K 168,652
  • Annual Sales, $ 68,560 K
  • Annual Income, $ -437,990 K
  • EBIT $ -479 M
  • EBITDA $ -458 M
  • 60-Month Beta 1.66
  • Price/Sales 21.89
  • Price/Cash Flow N/A
  • Price/Book 1.85

Options Overview Details

View History
  • Implied Volatility 71.62% (-9.43%)
  • Historical Volatility 43.58%
  • IV Percentile 14%
  • IV Rank 3.53%
  • IV High 520.93% on 11/04/25
  • IV Low 55.19% on 08/29/25
  • Expected Move (DTE 15) 0.55 (6.06%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 92
  • Volume Avg (30-Day) 248
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 7,654
  • Open Int (30-Day) 7,919
  • Expected Range 8.56 to 9.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.83
  • Number of Estimates 3
  • High Estimate $1.45
  • Low Estimate $0.47
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) +203.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.52 +6.92%
on 07/28/26
10.58 -13.89%
on 07/09/26
-0.93 (-9.26%)
since 07/02/26
3-Month
8.16 +11.64%
on 06/10/26
10.58 -13.89%
on 07/09/26
-0.90 (-8.99%)
since 05/05/26
52-Week
4.16 +119.25%
on 08/11/25
11.66 -21.87%
on 04/20/26
+4.00 (+78.28%)
since 08/05/25

Most Recent Stories

More News
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of...

VIR : 9.11 (-0.65%)
Vir Biotechnology: Can the Pipeline Actually Replace What the Partnership Revenue Isn't Delivering

Barchart Research What to Expect from VIR Earnings VIR Generated August 4, 2026 Current Price $9.17 EPS Estimate $$0.83 Consensus Rating Strong Buy Average Move 12.70% Vir Biotechnology: Can the Pipeline...

VIR : 9.11 (-0.65%)
Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23....

VIR : 9.11 (-0.65%)
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results...

VIR : 9.11 (-0.65%)
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased...

VIR : 9.11 (-0.65%)
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in “Best of EASL 2026” by EASL - Poster...

VIR : 9.11 (-0.65%)
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion...

VIR : 9.11 (-0.65%)
Can Vir Biotechnology's Hepatitis Pipeline Finally Justify the Astellas Collaboration Premium?

Barchart Research What to Expect from VIR Earnings VIR Generated May 5, 2026 Current Price $10.01 EPS Estimate $$-0.01 Consensus Rating Strong Buy Average Move 13.11% Can Vir Biotechnology's Hepatitis...

VIR : 9.11 (-0.65%)
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare...

VIR : 9.11 (-0.65%)
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results...

VIR : 9.11 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 9.67
2nd Resistance Point 9.52
1st Resistance Point 9.31
Last Price 9.11
1st Support Level 8.95
2nd Support Level 8.80
3rd Support Level 8.59

See More

52-Week High 11.66
Last Price 9.11
Fibonacci 61.8% 8.79
Fibonacci 50% 7.91
Fibonacci 38.2% 7.02
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.